Evaluation of Heart Failure Telemonitoring Eligibility Criteria
ConditionHeart Failure
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Clermont-Ferrand
About this trial
CARDIAUVERGNE is a heart failure telemonitoring system at Clermont-Ferrand's hospital. The aim of this study is to analyze the prognosis and evolution of patients after exclusion of telemonitoring. The patients were included from 1st January 2023 to 31st December 2024 and the monitoring was terminated for end of eligibility according to the French health authority criteria.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
adults
able to read and understand french
included in CARDIAUVERGNE telemonitoring program from 1st january 2023 to 31st december 2024 such as defined by the french health authorithy criteria (heart failure within 12 months or dyspnea at least NYHA 2 associated with NTproBNP of at least 1000pg/mL) and excluded by medical decision as no longer presenting eligibillity criteria
Disqualifiers
Patients leaving telemonitoring for other reasons (choice, death, medical reason, relocation, inobservance)
Trial population
Patients included in CARDIAUVERGNE telemonitoring that have been excluded as they no longer fulfill the inclusion criteria
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Composite criterion defined by the occurrence within one year following the end of remote monitoring of either cardiovascular death or heart failure worsening (hospitalization or unscheduled visit for heart failure)
Time frame
From telemonitoring exclusion up to a year afterSecondary outcomes
1
Amount of medical appointments
General practician and cardiology consultations
Time frame
From telemonitoring exclusion up to a year after2
Natriuretic peptides, NTproBNP, evolution
NTproBNP comparison at inclusion, exclusion and a year after exclusion for monitoring
Time frame
From inclusion until a year after exclusion3
Number of patients that could theoretically be re-included during follow up
Time frame
From telemonitoring exclusion up to a year after4
Determination of potential patient profiles more suitable to discontinue remote monitoring
Time frame
From inclusion up to a year after telemonitoring exclusionSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov